BPC-157 · research summary

Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.

Current reviews in musculoskeletal medicine · 2025. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Scoping review
“This scoping review aims to evaluate the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in the context of musculoskeletal healing.”

Subjects

Animals and humans
“BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regenerative properties across numerous animal models.”

Sample size

Three pilot studies in humans
“Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics.”

Reported findings

BPC-157 activates pathways including VEGFR2 and nitric oxide synthesis, promoting angiogenesis and tissue repair in animal models.
“It activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization.”
Human data are extremely limited, with only three pilot studies conducted and no adverse effects reported.
“Despite broad preclinical support, human data are extremely limited.”
There is a critical need for well-designed human trials to assess safety, efficacy, and clinical utility.
“This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine.”

Limitations stated by the authors

Minimal human data and lack of rigorous, large-scale trials
“No adverse effects were reported, but rigorous, large-scale trials are lacking.”

Source: PubMed 40789979 · DOI 10.1007/s12178-025-09990-7 · all study summaries

Reported findings

BPC-157 activates pathways including VEGFR2 and nitric oxide synthesis, promoting angiogenesis and tissue repair in animal models.

“It activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization.”

Human data are extremely limited, with only three pilot studies conducted and no adverse effects reported.

“Despite broad preclinical support, human data are extremely limited.”

There is a critical need for well-designed human trials to assess safety, efficacy, and clinical utility.

“This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine.”